Highest-materiality recent filing
Prestige Consumer Healthcare SVP Operations Jeffrey Zerillo to retire Aug 14, 2026
Jeffrey Zerillo, Senior Vice President, Operations, notified company of retirement on Aug 10, 2026.
Prestige Consumer Q1 revenue $265.7M (+6.5%), adj. EPS $0.98; raises FY outlook to $1.29-1.315B
Q1 revenue $265.7M (+6.5% YoY); organic sales growth 3.2% exceeded expectations.
Prestige Consumer Healthcare subsidiary issues $400M 6.250% senior notes due 2034
$400M aggregate principal of 6.250% senior notes due July 15, 2034 issued by Prestige Brands, Inc.
Prestige files 8-K/A with OTC Wellness Business Q1 2026 financials; net income $12.6M
OTC Wellness Business net sales $51.7M for Q1 2026, up 2.4% YoY from $50.5M.
Prestige closes LaCorium acquisition for ~$150M, prices $400M notes at 6.25% due 2034
Completed acquisition of LaCorium Health for ~$150M cash; LaCorium has ~$40M annual revenue, expected ~$12M EBITDA post-synergies.
Acquired OTC Wellness Business Q1 net sales $51.7M, net income $12.6M
Net sales of $51.7M for Q1 2026, up 2.4% from $50.5M in Q1 2025.
Prestige closes $1.045B acquisition of Breathe Right brand from Foundation
Purchase price $1.045B cash; net of $150M tax benefits, effective cost ~$900M.
Prestige Consumer reports FY26 adj EPS $4.38; acquires LaCorium Health for $150M
FY26 revenue $1,088.7M (-4.3% YoY); adjusted diluted EPS $4.38 vs $4.52 prior year.
Prestige Consumer Healthcare to acquire Breathe Right brand portfolio for $1.045B
Acquisition includes Breathe Right, Dimetapp, Anbesol brands; trailing revenue $200M, EBITDA $95M.
Prestige Q3 revenue $283.4M, down 2.4% YoY; adjusted EPS $1.14 vs $1.22
GAAP diluted EPS $0.97; adjusted diluted EPS $1.14 (down from $1.22); net income $46.7M.
Prestige Consumer Q2 adj EPS $1.07 beats prior year; raises FY adj EPS guidance to $4.54-$4.58
Q2 revenue $274.1M (-3.4% YoY); diluted EPS $0.86 vs $1.09; adjusted EPS $1.07.
Prestige Q1 revenue down 6.6%, misses; acquires Pillar5 for CAD 150M, cuts FY26 outlook
Revenue $249.5M (-6.6% YoY); diluted EPS $0.95 ($0.90 adjusted).
Prestige Q4 revenue $296.5M, adj EPS $1.32; FY25 adj EPS $4.52; FY26 outlook $4.70-4.82
Q4 revenue $296.5M (+7.0% YoY, organic +7.9%); diluted EPS $1.00 GAAP, adjusted $1.32 (vs $1.02 prior year).
Prestige Q3 FY2025 EPS $1.22 (+15% YoY); raises FY25 adjusted EPS outlook to ~$4.50
Q3 revenues $290.3M (+2.7% YoY); record quarterly sales and EPS.
Christine Sacco, CFO since 2016, appointed COO/CFO effective Jan 6, 2025; will oversee supply chain.
Prestige Consumer Healthcare Q2 revenue $283.8M, diluted EPS $1.09; reaffirms FY2025 outlook
Revenue $283.8M (-0.9% YoY) slightly ahead of expectations; diluted EPS $1.09 vs $1.07 prior year.
Prestige Consumer Q1 revenue $267.1M beats expectations; reaffirms FY2025 outlook
Q1 GAAP EPS $0.98, adjusted EPS $0.90; revenue down 4.4% YoY but ahead of internal plan.
Q4 revenue $277.0M (-2.9% ex-FX); non-GAAP adj. diluted EPS $1.02 vs $1.07 prior year.
Prestige Consumer Healthcare elects John F. Kelly, former Pfizer VP, to Board
John F. Kelly, former Vice President Quality Operations and EHS at Pfizer, elected to PBH Board on May 7, 2024.
Prestige Consumer Q3 revenue $282.7M (+2.6% YoY), raises FY EPS outlook to ~$4.33
Diluted EPS $1.06 in Q3, up 2.2% vs $1.04 prior year; net income $53.0M.
Revolving credit commitments increased by $41.5M (exhibit shows $41.5M, not $25M cited in filing summary).
Prestige Consumer Healthcare Q2 rev $286.3M, EPS $1.07, leverage down to 3.0x
Q2 FY2024 revenue $286.3M, slightly below prior-year record of $289.3M but ahead of internal outlook.
Prestige Consumer Healthcare Q1 revenue $279.3M (+0.8% YoY); reaffirms FY2024 outlook
Revenue $279.3M, up 0.8% YoY (1.8% ex-FX); net income $53.3M, diluted EPS $1.06 vs $1.09 prior year.
Prestige Consumer Healthcare reports record FY23 revenue $1.1277B; guides FY24 EPS $4.27-$4.32
Q4 revenue $285.9M (+7.1% YoY, +8.0% organic); adjusted EPS $1.07 vs $0.91 prior year.
Prestige Q3 revenue $275.5M (+0.4%), EPS $1.04 (+5.1%); guides FY23 EPS ~$4.18
Q3 revenue $275.5M (+0.4% YoY; +1.8% ex-currency); diluted EPS $1.04 (+5.1% vs $0.99).
Prestige Q2 revenue $289.3M (+4.7% YoY), EPS $1.02; reaffirms FY2023 outlook
Record Q2 revenue $289.3M (+4.7% YoY, +5.5% ex-currency); diluted EPS $1.02, ahead of expectations.
Prestige Q1 FY2023 revenue $277.1M, EPS $1.09, reaffirms full-year guidance
Revenue $277.1M, +2.9% YoY; organic revenue (ex-Akorn, FX) declined 1.2%.
Q4 revenue $266.9M (+12.3% YoY); full-year revenue $1,086.8M (+15.2% YoY).
Prestige Q3 revenue $274.5M (+14.9% YoY), EPS $0.99 (+22.2%); raises FY22 outlook
Revenue $274.5M, up 14.9% YoY; organic growth 8.8% excluding currency and Akorn acquisition.
Prestige Q2 fiscal 2022 revenue record $276.2M; raises full-year guidance
Record Q2 revenue $276.2M (+16.3% YoY); organic growth 10.5% ex-Akorn and FX.
Prestige Consumer Healthcare Q1 revenue $269.2M (+17.3%), EPS $1.14 (+32.5%); raises FY22 outlook
Revenue $269.2M, up 17.3% YoY; diluted EPS $1.14, up 32.5% vs prior year.
Prestige completes $230M acquisition of TheraTears from Akorn, refinances term loan.
Acquired TheraTears and other OTC brands from Akorn Operating Company for $230M cash, closed July 1, 2021.
On August 10, 2026, Jeffrey Zerillo notified Prestige Consumer Healthcare Inc. (the “Company”) of his decision to retire from his position as Senior Vice President, Operations and from all other positions he holds with the Company, effective August 14, 2026.
On January 6, 2025, Prestige Consumer Healthcare Inc. (the “Company”) announced that the Company’s Chief Financial Officer, Christine Sacco, age 49, has also been appointed Chief Operating Officer, effective January 6, 2025.
The Company today announced that John F. Kelly, former Vice President Quality Operations and Environment, Health & Safety at Pfizer Inc. was elected to the Company’s Board of Directors on May 7, 2024.
Max materiality 0.85 · Median 0.75 · Most common event earnings